update deskIsrael News

Patient receives new knee made from coral, thanks to Israeli startup company

Agili-C, which is made of a material derived from the exoskeletons of coral, is currently undergoing clinical studies centering around the regeneration of damaged cartilage and bone. More than 70 patients have been treated with the implant so far worldwide.

Inserting the Agili-C implant into damaged bone. Source:  Cartiheal.com
Inserting the Agili-C implant into damaged bone. Source: Cartiheal.com

Israel has just completed its first successful knee surgery using a coral-based implant invented by an Israeli startup.

Earlier this month, a 30-year-old patient who had undergone several unsuccessful knee surgeries in the past, received an Agili-C implant at Hadassah University Medical Center on Jerusalem’s Mount Scopus campus, created by the Kfar Saba-based CartiHeal startup.

Agili-C, which is made of a material derived from the exoskeletons of coral, is currently undergoing clinical studies centering around the regeneration of damaged cartilage and bone. More than 70 patients have been treated with the implant so far worldwide.

Dr. Adi Friedman, who performed the operation, said the surgery could be an important milestone in knee surgery.

“The need for an implant that leads to the regrowth of damaged cartilage is genuinely needed in the orthopedic world, and we hope that the [clinical] trial will succeed, and that the implant will be the breakthrough that we have been waiting for for many years,” he said in a statement.

You have read 3 articles this month.
Register to receive full access to JNS.

Just before you scroll on...

Israel is at war. JNS is combating the stream of misinformation on Israel with real, honest and factual reporting. In order to deliver this in-depth, unbiased coverage of Israel and the Jewish world, we rely on readers like you. The support you provide allows our journalists to deliver the truth, free from bias and hidden agendas. Can we count on your support? Every contribution, big or small, helps JNS.org remain a trusted source of news you can rely on.

Become a part of our mission by donating today
Topics
Comments
Thank you. You are a loyal JNS Reader.
You have read more than 10 articles this month.
Please register for full access to continue reading and post comments.